How much is TransactRx worth in 2026?

TransactRx has a current valuation of N/A based on their Buyout/LBO (Add-on)† round and secondary market data.

How much funding has TransactRx raised?

TransactRx has raised N/A in total funding across 1 funding rounds.

TransactRx

Enterprise Systems (Healthcare)

TransactRx valuation and funding history | Last updated: June 17, 2022 | 1 funding rounds

Current Valuation

N/A

As of June 17, 2022

Total Funding Raised

N/A

Across 1 round

Last Round

Buyout/LBO (Add-on)†

Amount undisclosed

Last Funding

Jun 2022

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
June 17, 2022	Buyout/LBO (Add-on)†	Undisclosed	N/A	-

Valuation Analysis

Current Valuation Metrics

TransactRx is currently valued at N/A as of June 17, 2022.

Track TransactRx Valuation Updates

Get notified when TransactRx raises new funding or valuation changes

Explore More Data

Detailed analysis for TransactRx

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock TransactRx's valuation history, funding rounds, and growth metrics.

No credit card required

What is TransactRx Worth in 2026?

TransactRx is a leading private company in the Enterprise Systems (Healthcare) sector. Track TransactRx's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How TransactRx Valuation is Determined

Private company valuations like TransactRx's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.